NUTXHealthcare · Medical Care FacilitiesThe 5 Wall Street analysts covering Nutex Health, Inc. hold a median 12-month price target of $300 — +43.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 19 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Nutex Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (99): The business earns solid, repeatable profits on what it owns.
Volatility (12): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NUTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +43.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Sept 2026 | B. Riley Securities | Maintains | Buy | $290 → $325 |
| 11 Aug 2026 | Lake Street | Maintains | Buy | $235 → $310 |
| 11 Aug 2026 | Lake Street | Maintains | Buy | — |
| 26 June 2026 | B. Riley Securities | Initiates | Buy | $290 |
| 26 June 2026 | B. Riley Securities | Initiates | Buy | — |
| 2 June 2026 | Lake Street | Initiates | Buy | — |
| 26 Aug 2025 | Maxim Group | Maintains | Buy | — |
| 10 July 2025 | Benchmark | Reiterates | Buy | — |
| 20 May 2025 | Maxim Group | Maintains | Buy | — |
| 15 May 2025 | Benchmark | Maintains | Buy | — |
| 9 Apr 2025 | Benchmark | Maintains | Buy | — |
| 8 Apr 2025 | Maxim Group | Maintains | Buy | — |
| 13 Feb 2025 | Maxim Group | Maintains | Buy | — |
| 12 Nov 2024 | Benchmark | Maintains | Buy | — |
| 12 Nov 2024 | Maxim Group | Maintains | Buy | — |
| 18 Sept 2024 | Maxim Group | Initiates | Buy | — |
| 21 Aug 2024 | Benchmark | Maintains | Buy | — |
| 25 Jan 2024 | Benchmark | Maintains | Buy | — |
| 14 Nov 2023 | Benchmark | Maintains | Buy | — |
| 29 Aug 2023 | Benchmark | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NUTX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, Nutex Health, Inc. returned +124.6% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 61% of US stocks
Cheaper than 56% of US stocks
Cheaper than 27% of US stocks
Cheaper than 55% of US stocks
Higher than 14% of US stocks
Higher than 24% of US stocks
Higher than 80% of US stocks
Higher than 98% of US stocks
Higher than 83% of US stocks
Higher than 94% of US stocks
Higher than 99% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Nutex Health, Inc. has a market value of $1.4B and an enterprise value of $1.7B.
Revenue in the twelve months to 30 June 2026: $846.7M. The latest quarter shrank 13.6% year on year.
Net income over the same four quarters: $272.5M, a 32.2% net margin.
Free cash flow in the twelve months to 30 June 2026: $274.2M.
Nutex Health, Inc. spent $84.1M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 8.1×; forward P/E: 10.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Nutex Health, Inc. employs 1,037 people — $817K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Nutex Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlighted NUTX among five stocks showing strong recent price momentum amid a volatile September, noting the strength is backed by improving earnings expectations.
Why it matters — NUTX watchers would note that the stock was identified for recent price strength supported by improving earnings expectations, a positive signal in a volatile market.
Zacks Investment Research reports that Nutex Health (NUTX) passed its "Recent Price Strength" screening criterion, positioning the stock as a potential candidate for trend investing. The piece highlights the stock's current movement as of note for investors.
Why it matters — NUTX watchers may take note because the stock has cleared a momentum-based screen, indicating recent price strength worth following.
Nutex Health issued an update regarding a previously announced cybersecurity event. The company provided new information to the public about the incident via a press release.
Why it matters — A cybersecurity event update could indicate operational or data-security concerns that NUTX investors and watchers should monitor.
Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from a cyberattack on Nutex Health Inc. The attack, claimed by the Gentlemen ransomware group, involved theft of patient and employee data, and the firm is offering free case evaluations to affected individuals.
Why it matters — NUTX watchers would care because the breach and resulting class action investigation could expose the company to legal, financial, and reputational risks.
Zacks Investment Research published a piece examining whether Nutex Health Inc. (NUTX) qualifies as a top momentum stock pick for investors. The article poses the question of whether the company has the characteristics to be a strong momentum holding.
Why it matters — The report highlights NUTX in the context of momentum investing, giving stock watchers insight into how the company is being evaluated by a major research provider.
The 5 Wall Street analysts covering Nutex Health, Inc. have a median 12-month price target of $300, with estimates ranging from $200 to $325. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Nutex Health, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nutex Health, Inc. 88 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, Nutex Health, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +43.7% from the last close, and Ticker Nerd's factor model ranks Nutex Health, Inc. 88 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Nutex Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NUTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $200 to $325 over the next 12 months.
Nutex Health, Inc. returned +124.6% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Nutex Health Inc. is a healthcare management and operations company that provides care delivery and support services through its Hospital Division and Population Health Management Division.
The most recent item we track (Zacks Investment Research, 17 Sept 2026): "5 Stocks With Recent Price Strength Amid a Volatile September". Zacks Investment Research highlighted NUTX among five stocks showing strong recent price momentum amid a volatile September, noting the strength is backed by improving earnings expectations.
Nutex Health Inc. is a healthcare management and operations company that provides care delivery and support services through its Hospital Division and Population Health Management Division. Nutex Health operates a network of micro hospitals, specialty hospitals, and hospital outpatient departments that offer emergency care, inpatient services, behavioral health, imaging, laboratory testing, and pharmacy services. Its population health business builds and manages provider networks, including independent physician associations, and provides administrative and technology support through a cloud-based platform. The company also includes a real estate segment that owns and leases hospital properties. Nutex Health serves patients and physician groups across multiple U.S. states, with a model centered on integrated local healthcare access and coordinated care operations.
CEO Dr. Thomas T. Vo M.B.A., M.D. · 1,037 employees · United States · https://www.nutexhealth.com
